AMENDMENT NO. 2 TO OPTION AGREEMENTOption Agreement • April 6th, 2015 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 2 TO OPTION AGREEMENT (the “Second Amendment”), dated February 6, 2015,(the “Second Amendment Effective Date”), amends that certain Option Agreement dated October 27, 2014 (the “Original Agreement”) as amended by the First Amendment to the Option Agreement dated January 5, 2015 (the “First Amendment” and together with the Original Agreement, the “Option Agreement”), between Amarantus Bioscience Holdings, Inc., a Nevada corporation (“Amarantus”) and Lonza Walkersville, Inc., a Delaware corporation (“Lonza”). The parties identified above are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties.” Capitalized terms not defined herein shall have the meanings assigned to them in the Option Agreement.
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 6th, 2015 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT TO ASSET PURCHASE AGREEMENT, dated January 30, 2015, (the “Amended Agreement”), is intended to amend that certain Asset Purchase Agreement dated November 7, 2014 (the “Original Agreement”), by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation (“Amarantus”), Regenicin, Inc., a Nevada corporation (“Regenicin”), Clark Corporate Law Group, LLP (fka Cane Clark, LLP, hereinafter “CCLG”), and Gordon & Rees, LLP (“Gordon & Rees”), but only as to the rights and obligations of Amarantus, Regenicin and CCLG (the “Affected Parties”). As a result, the only signatories to this Amended Agreement shall be the Affected Parties.
